Nasdaq

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
Seeking Alpha

ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial ...

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent ...
Business Wire

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to ...
The American Journal of Managed Care

Meta-Analysis Finds No Significant NSCLC Survival Differences With ICIs, but Trial Diversity Remains Limited

ICIs have transformed NSCLC treatment, but disparities in trial enrollment and efficacy reporting persist, limiting insights into treatment benefits across demographics. A meta-analysis of 21 trials ...
Seeking Alpha

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in ...

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 ...